# Contineum Therapeutics, Inc.: overview

CTNM · Nasdaq · CIK 1855175 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ctnm.md) · [Financials](/companies/ctnm/financials.md) · [Filings](/companies/ctnm/filings.md) · [Insiders](/companies/ctnm/insiders.md)

Latest reported revenue: [$0](/filings/0001437749-25-006458.md) for Q4 FY2024, three months to 2024-12-31, from the 10-K filed Mar 6, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-25-006458).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001437749-24-033616.md) | [0.0 d](/filings/0001437749-25-006458.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.40)](/filings/0001437749-24-033616.md) | not reported | [(0.62)](/filings/0001628280-26-030614.md) | [(0.62)](/filings/0001628280-26-051054.md) | not reported | not reported | [(0.39)](/filings/0001628280-26-030614.md) | [(0.40)](/filings/0001628280-26-051054.md) |
| Free cash flow | $m | [(6.3) d](/filings/0001437749-25-032427.md) | [(10.4) d](/filings/0001628280-26-015165.md) | [(14.5)](/filings/0001628280-26-030614.md) | [(15.7) d](/filings/0001628280-26-051054.md) | [(12.3) d](/filings/0001437749-25-032427.md) | [(13.1) d](/filings/0001628280-26-015165.md) | [(16.6)](/filings/0001628280-26-030614.md) | [(11.5) d](/filings/0001628280-26-051054.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: |
| Revenue | $m | [50.0](/filings/0001437749-25-006458.md) | [0.0](/filings/0001437749-25-006458.md) | not reported |
| Gross margin | % | not reported | not reported | not reported |
| Operating margin | % | [32.2%](/filings/0001437749-25-006458.md) | not reported | not reported |
| Net margin | % | [45.4%](/filings/0001437749-25-006458.md) | not reported | not reported |
| Diluted EPS | $ per share | [0.08](/filings/0001437749-25-006458.md) | [(2.18)](/filings/0001628280-26-015165.md) | [(2.17)](/filings/0001628280-26-015165.md) |
| Free cash flow | $m | [18.9](/filings/0001437749-25-006458.md) | [(33.4)](/filings/0001628280-26-015165.md) | [(55.5)](/filings/0001628280-26-015165.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ctnm/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $46.6m | 2,841,334 |  | Unchanged |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $44.8m | 2,734,836 |  | Not compared |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $35.6m | 2,734,836 |  | Not compared |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $33.8m | 2,064,345 |  | Added +1,395,222 |
| [JOHNSON & JOHNSON](/funds/200406.md) | 2026-06-30 | $32.4m | 1,979,173 |  | Unchanged |
| [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $30.1m | 1,839,227 |  | Unchanged |
| [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $25.0m | 1,522,793 |  | Reduced −162,842 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $21.7m | 1,321,356 |  | Added +107,183 |
| [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $20.6m | 1,255,592 |  | Unchanged |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $17.0m | 1,040,130 |  | Added +225,259 |

## Recent filings

[All 188 filings](/companies/ctnm/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-14 | 20:07 ET | [8-K](/filings/0001628280-26-061834.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-061834 |
| 2026-07-30 | 20:11 ET | [10-Q](/filings/0001628280-26-051054.md) | Quarterly report, period 2026-06-30 | 0001628280-26-051054 |
| 2026-07-30 | 20:08 ET | [8-K](/filings/0001628280-26-051051.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-051051 |
| 2026-07-13 | 20:15 ET | [8-K](/filings/0001628280-26-048023.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-048023 |
| 2026-06-26 | 20:48 ET | [8-K](/filings/0001628280-26-045804.md) | 5.07 Shareholder vote results | 0001628280-26-045804 |
| 2026-05-05 | 20:24 ET | [10-Q](/filings/0001628280-26-030614.md) | Quarterly report, period 2026-03-31 | 0001628280-26-030614 |
| 2026-05-05 | 20:09 ET | [8-K](/filings/0001628280-26-030522.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-030522 |
| 2026-04-30 | 20:08 ET | [DEF 14A](/filings/0001628280-26-028881.md) | Proxy statement, period 2026-06-26 | 0001628280-26-028881 |
| 2026-04-30 | 20:07 ET | [8-K](/filings/0001628280-26-028876.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-028876 |
| 2026-03-05 | 21:09 ET | [10-K](/filings/0001628280-26-015165.md) | Annual report, period 2025-12-31 | 0001628280-26-015165 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-015165.md), filed Mar 5, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1855175
- Tickers: CTNM
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.